Home » Newsletters » BioWorld Science

BioWorld Science

March 7, 2016

View Archived Issues

BioPharmX initiates phase IIa study of BPX-01 for acne

First patient dosed in phase I trial of BAX-826 for the treatment of hemophilia A

Akinion ceases further development of AKN-028 due to safety concerns

EMA grants eligibility for submission of XBiotech's MAA for Xilonix

APO-010 screening protocol approved by ethics committee

Lessons learned from nonrandomized trial of favipiravir in patients with Ebola virus disease

Novartis initiates phase I trial of LXS-196 for metastatic uveal melanoma

Novel mutations in TNNT1 gene described as cause of myopathies

UCLA sells Xtandi royalty rights to Royalty Pharma

Bristol-Myers Squibb patent describes S1P1 receptor agonists

University of Washington patents methionyl-tRNA synthetase inhibitors

PTC Therapeutics divulges anti-infective agents

FDA approves Imbruvica for first-line treatment of CLL

FDA approves Idelvion for hemophilia B

Antibe Therapeutics cleared to begin phase II study of ATB-346

PeptiDream and Lilly in technology license agreement

U.S. fast track designation granted to MEDI-8852 for patients with type A strain influenza

Merck & Co. and Mectizan Donation Program donate to END fund

Total levels of IgE are elevated in patients with hidradenitis suppurativa

Oxford BioMedica and Immune Design in expanded collaboration and license agreement

LEADER trial demonstrates cardiovascular benefit of Victoza

3SBio obtains IND clearance in China for PEG-irinotecan

Plexxikon initiates phase I study of PLX-73086

EMA launches new PRIME program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...